Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02223819 · ClinicalTrials.gov registry record · Phase 2
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
A Phase 2 study of Uveal Melanoma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 4
- Study locations
NCT02223819: Completed Phase 2 study of Uveal Melanoma, sponsored by Columbia University.
NCT02223819 is a Phase 2 study of Uveal Melanoma that has completed, run by Columbia University. The registered enrollment target is 34 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02223819, a Phase 2 study of Uveal Melanoma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.
Primary Outcome
RFS rate will be defined as the percentage of patients who do not experience any new tumor growth at any site on the body distant from the primary site or death from any cause from the time of study entry to the end of the relevant timepoint. RFS probabilities were estimated using Kaplan-Meier method.
Conditions Studied
Interventions
- DRUG Crizotinib
Study Locations (4)
New York
- Columbia Univeristy Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
What the finished NCT02223819 record still lists
NCT02223819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Crizotinib is the first listed.
NCT02223819 reports a single indexed study location in New York, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT02223819 about?
NCT02223819 is a clinical study titled "Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy". The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in th...
What is the current status of trial NCT02223819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2015-03. Estimated completion is 2019-07-03.
What conditions does trial NCT02223819 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT02223819?
The interventions under investigation include: Crizotinib (DRUG).
Who is sponsoring clinical trial NCT02223819?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02223819 being conducted?
This trial has 4 study locations across Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02223819's enrollment target sits among peer trials
34 21st of 29 higher than 9 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia